Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

Mavacamten did not significantly improve exercise capacity as assessed by peak oxygen uptake or improve patient-reported health status compared with placebo in patients with symptomatic nonobstructive ...

Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...

A newly released ACC Expert Consensus Decision Pathway (ECDP) focused on the clinical assessment, management and trajectory of patients hospitalized with heart failure (HF) includes revisions to the ...

As the new year begins, the landscape of cardiovascular medicine is undergoing a remarkable transformation, driven by groundbreaking technologies and innovative approaches that promise to ...

The U.S. Food and Drug Administration (FDA) has approved the FARAPULSE Pulsed Field Ablation System for isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, ...

The Centers for Medicare and Medicaid Services (CMS) has proposed a change in methodology to indirect practice expense (PE) payment in the proposed 2026 Medicare Physician Fee Schedule (PFS), which ...

This episode is part of ACC’s ongoing initiative to advance heart failure (HF) care through team-based collaboration and patient-centered decision-making. Drs. Marty Tam, Lindsey Aurora, Leslie Davis, ...

The ACC's Clinical Trials Research (CTR): Upping Your Game Program is a year-long professional development opportunity for cardiologists, cardiac surgeons and doctorate–level trained cardiovascular ...

We are a young, vibrant section dedicated to adding value to Section members interested in Innovation across the cardiovascular spectrum. Our section is member-driven and focused on all aspects of ...

Patients with heart failure (HF) who had an interatrial shunt inserted did not see any significant benefits overall, compared with those who underwent a placebo procedure, after a median 22-month ...